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Dynamic contrast-enhanced CT in patients
treated with sorafenib and erlotinib
for non-small cell lung cancer: a new
method of monitoring treatment?
Abstract Objective We investigated
the feasibility of serial dynamic con-
trast-enhanced computed tomography
(DCE-CT) in patients with advanced/
metastatic non-small cell lung cancer
(NSCLC) receiving anti-angiogenic
(sorafenib) and anti-EGFR (erlotinib)
treatment, and correlated tumour
blood ﬂow (BF) with treatment
outcome. Methods DCE-CTs were
performed at baseline and 3 and
6weeks after starting treatment.
Tumour BF, calculated with the
maximum slope method, and
percentage change were measured in
23 patients (14 male; median age 59
years). Tumour BF was compared at
baseline and weeks 3 and 6; the
relation with RECIST/Crabb
response and progression-free
survival (PFS) was assessed.
Results Mean tumour perfusion
decreased from 39.2ml/100g/min at
baseline to 15.1ml/100g/min at week
3( p<0.001) and 9.4ml/100g/min at
week 6 (p<0.001). Tumour perfusion
was lower in RECIST and Crabb
responders versus non-responders at
week 3 (4.2 versus 17.7ml/100g/min,
p=0.03) and week 6 (0 versus
13.4ml/100g/min, p=0.04). Patients
with a decrease larger than the
median at week 6 tended to
have a longer PFS (7.1 versus
5.7months, p=0.06). Conclusion
Serial DCE-CTs are feasible
in patients with NSCLC and
demonstrated a signiﬁcant decrease in
tumour BF following sorafenib/
erlotinib therapy. Early changes in
tumour BF correlated with objective
response and showed a trend towards
longer PFS.
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Introduction
Angiogenesis, the formation of new blood vessels, is a
key process in tumorigenesis [1]. Angiogenesis inhibitors
have yielded promising results in oncology. They are
considered largely cytostatic, inhibiting tumour growth
and progression rather than causing tumour regression.
Furthermore, anatomical changes lag behind functional
changes and tumour shrinkage does not necessarily
correlate with patient survival [2]. The standard anatomy-
based response assessment using the Response Evaluation
Criteria in Solid Tumors (RECIST), therefore seems
inadequate for the early evaluation of the efﬁcacy of these
drugs [3, 4].
A logical approach to evaluating the effect of angio-
genesis inhibitors is to assess their proposed direct target: the
tumour vasculature. The current gold standard technique to
determine tumour vascularity is measurement of microvessel
density (MVD) on tissue samples [5]. However, this invasive
method is unsuitable for serial measurements. Furthermore,
only focalregions are assessed whereastumour vasculature is
heterogeneous. Non-invasive functional imaging techniques
may be superior, providing information on whole tumour
volumes. Traditionally dynamic contrast-enhanced magnetic
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Maastricht, the Netherlandsresonance imaging (DCE-MRI) has been used. However, its
application in lung cancer is limited by a low spatial
resolution. With the development of multi-detector CT and
user-friendly perfusion software programs, the quantiﬁcation
of perfusion parameters using dynamic contrast-enhanced
CT (DCE-CT) is increasingly being investigated in oncology.
Currently, there are limited data available concerning
the application of DCE-CT for response monitoring of
angiogenesis inhibitors. However, this does appear to be
feasible and changes in tumour vascular parameters have
been demonstrated [6–10]. In non-small cell lung cancer
(NSCLC) whole tumour perfusion measured by DCE-CT
has been shown to be reproducible [11, 12]. Perfusion
parameters measured before surgery for lung cancer
correlate with MVD in resected tumour specimens,
implying a reliable assessment of tumour vascularity [13,
14]. No studies have, to our knowledge, assessed DCE-CT
in monitoring response to angiogenesis inhibitors in
NSCLC and how this correlates with patient outcome [15].
In the context of a phase II trial we prospectively evaluated
the tumour blood ﬂow (BF) measured by DCE-CTin patients
with advanced or metastatic NSCLC treated with the multi-
targeted tyrosine kinase angiogenesis inhibitor sorafenib and
the anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor erlotinib. Both have demonstrated anti-
tumour efﬁc a c yi nN S C L C[ 16–19]. The study aimed to
investigate the feasibility of serial DCE-CTs in NSCLC
patients receiving combined anti-angiogenic and anti-EGFR
treatment, to determine the effect of sorafenib plus erlotinib
on tumour BF and to relate tumour BF to treatment outcome.
Materials and methods
Patient selection
The study was conducted within a multi-centre phase II
clinical trial of erlotinib and sorafenib in chemotherapy-
naïve patients with inoperable, locally advanced/meta-
static NSCLC (NCT00722969). Two out of the three
participating centres took part in this side study. Approval
was obtained from each centre’s institutional review
board. All patients provided written informed consent.
Between December 2007 and October 2008, 34 of the
50 patients in the phase II trial were prospectively enrolled
onto this study. Inclusion criteria included Eastern Cooper-
ative Oncology Group performance status 0–1, estimated
life expectancy≥12 weeks and primary tumour size≥1c m
on CT. Patients with a known contrast medium allergy, the
inability to hold their breath for long enough or the inability
to obey breath-hold commands were ineligible.
Study design
Erlotinib (150 mg/day) and sorafenib (800 mg/day) were
orally self-administered and continued until disease progres-
sion, unacceptable toxicity and/or withdrawal of consent.
Dose reductions were allowed but did not occur within the
ﬁrst 3 weeks of treatment. Clinical assessments were
scheduled every 3 weeks for the ﬁrst 3 months then every
6 weeks. DCE-CT was performed at the same time as pre-
treatment CTs and 3 and 6 weeks after starting treatment.
Tumour anatomic size was evaluated at baseline, weeks 3 and
6 and then 6-weekly by standard contrast-enhanced CTof the
thorax. Tumour anatomic response was assessed by change in
size according to RECIST 1.0 and an alternative method
incorporating tumour cavitation as proposed by Crabb et al. (a
target lesion is measured by subtracting the longest diameter
of a cavity [zero if no cavity present] from the longest
diameter of the lesion) [20].
DCE-CT acquisition protocol
The DCE-CTs were obtained by using 64-slice multi-
detector CT (MDCT) (Somatom Sensation, Siemens, Erlan-
gen, Germany). An initial non-enhanced CT study (80 kV,
120 mAs , collimation 24×1.2 mm, pitch 1.15, rotation time
0.5s,ﬁeldofview380mm,slicewidth5mm,reconstruction
increment5mm)wasperformedtodetermine thepositionof
the primary tumour. The subsequent dynamic spiral CT
series encompassed the whole primary tumour volume. A
50-ml intravenous bolus of a low-osmolarnon-ioniccontrast
agent with an iodine concentration of 300 mg/ml (Ultravist-
300 Iopromide; Schering A.G., Berlin, Germany) was
injected over 6.25 s (8 ml/s), using an injection pump
through an 18-gauge needle. After a start delay of 4 s,
dynamic acquisition of image data was obtained over
approximately 40 s, within one breath-hold period. CT
parameters were100kVand80mAs ata slicecollimation of
64×0.6 mm anda rotation time of0.5 s.Temporal resolution
was 4 s (1-s acquisition time; interscan delay 3 s). The
images were reconstructed by using a slice thickness of
5 mm, with a reconstruction increment of 5 mm. Dynamic
CTs were performed with a ﬁxed lower tube current of
80 mAs to reduce radiation exposure. After this dynamic
acquisition and following an additional 80-ml bolus of the
samelow-osmolarnon-ioniccontrast agentat an injection rate
of3ml/sanda30-sdelay,aroutine,post-contrast,spiralCTof
the thorax (120 kV; 130 mAs with care dose automated
exposure control) was obtained by using 5-mm-thick sections
with a contiguous reconstruction algorithm. For a z-axis
coverage of 5 cm (which is variable and depends on tumour
size) the effective dose, expressed according to the Interna-
tional Commission on Radiological Protection recommenda-
tions, was 1.2 mSv for the non-enhanced CT and 4.4 mSv
(10×0.44 mSv) for the dynamic CT protocol [21–23].
Post-processing analysis
Image registration (3D rigid-body) was performed with a
commercially available 3D image fusion program (Vinci
2.36.0, Max-Planck Institute for Neurological Research,
2891Cologne). For the quantiﬁcation of tissue perfusion and
for the creation of blood ﬂow maps, the software program
Basama Perfusion 3.0.7.1 (Kanazawa, Ishikawa, Japan)
was used [24, 25]. This program uses the maximum slope
method, calculating perfusion as the maximum slope of
the tumour time–density curve divided by the peak arterial
enhancement [26]:
F
V
¼
d
dt cðtÞ ½  max
aðtÞmax
Table 1 Patient characteristics and outcome
Characteristic Patients included in original
clinical trial
Patients included in
perfusion study
Patients included in
perfusion analysis
(n=50) (n=34) (n=23)
No. of patients % No. of patients % No. of patients %
Sex Female 22 44 14 41 9 39
Male 28 56 20 59 14 61
Age, years Median 60 60 59
Range 41–78 41–78 41–78
Ethnicity Caucasian 45 90 30 88 20 87
Black 2 4 2 6 2 9
Asian 3 6 2 6 1 4
ECOG PS 0 30 60 19 56 15 65
12 0 4 0 1 54 4 8 3 5
Tumour histology Adenocarcinoma 36 72 26 77 17 74
Squamous 5 10 3 2 9 9
Large cell 6 12 2 6 2 9
NSCLC NOS 3 6 3 9 2 9
Tumour stage
a IIIB 13 26 11 32 5 22
IV 37 74 23 68 18 78
RECIST 1.0 Responder
b 14 28 12 35 6 26
Non-responder
c 31 62 17 50 15 66
Not evaluable 5 10 5 15 2 9
Median PFS, months 4.6 5.6 5.9
Median OS, months 12.0 12.4 12.4
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, BAC bronchioloalveolar carcinoma, NOS not otherwise speciﬁed, EGFR
epidermal growth factor receptor, RECIST Response Evaluation Criteria in Solid Tumors version 1.0 [39], PFS progression-free survival, OS overall survival
aTumour stage according to the 6th edition of TNM Classiﬁcation of Malignant Tumours [40]
bResponder = patient with complete response or partial response
cNon-responder = patient with stable disease or progressive disease
Fig. 1 Anexampleof serial DCE-CTand perfusionparameter maps
of the thorax (axial plane) of a study patient. a Tumour blood ﬂow at
baseline was 95.2 ml/100 g/min. b After 3 weeks of treatment
tumour cavitation was present and the blood ﬂow had decreased to
18.2 ml/100 g/min. c After 6 weeks there was more extensive tumour
cavitation. Blood ﬂow in the remaining peripheral tumour tissue had
decreased to 7.0 ml/100 g/min
2892where F is blood ﬂow, V is blood volume, c(t) is the
contrast density in the tissues and a(t) is the contrast
density in the feeding artery (aorta). Regions of interest
(ROIs) were drawn within the aorta and within the tumour
(as large as possible to minimise noise but excluding large
cavitations and extensive areas of necrosis [density<
5 HU]) (see Fig. 1). Tumour ROIs were deﬁned in all
slices that covered the tumour and the tumour BF was
calculated as follows:
P
all slicesðtumourROI densityðinHUÞ surfaceareaðinmm2ÞslicexÞ
P
allslicestumourROIsurfaceareasðinmm2Þ
Blood ﬂow is expressed in millilitres per 100g of
tumour tissue per minute (ml/100 g/min). Imaging
analysis was performed by an experienced radiologist
blinded to the clinical outcome.
Statistical analysis
Baseline (pre-treatment) tumour BF was compared with
tumour BF after 3 and 6 weeks of treatment using the non-
parametric Wilcoxon signed-rank test. Tumour BF and
percentage change in tumour BF were compared between
responders (deﬁned as those achieving an objective
complete or partial response [PR] according to the
RECIST and Crabb methods) versus non-responders
(deﬁned as those having stable disease [SD] or progres-
sive disease [PD]) using the Mann–Whitney test. Log-
rank statistics were used to test associations with
progression-free survival (PFS) and overall survival
(OS). Two-tailed p<0.05 was considered statistically
signiﬁcant.
Results
The study protocol was easily integrated into the clinical
routine. No side effects were seen and all patients
tolerated the dynamic CT well. The clinical characteristics
of the 34 patients included did not differ from the entire
study population of the clinical trial (Table 1). Thirty
patients had at least two DCE-CTs. Reasons for less than
two CT being performed were: logistical problems (n=2);
discontinuation of study medication (n=1) and withdrawal
of consent (n=1). Seven patients were excluded from the
perfusion analysis. Reasons for exclusion were: inclusion
errors (tumour too small [n=3]; tumour not evaluable due
to post-obstructive atelectasis and a large pleural effusion
[n=1]); beam-hardening artefact due to the close prox-
imity of the tumour to a major blood vessel (n=2); and
technical imaging error (n=1). Of the 23 patients included
in the analysis 19 had tumour BF measurements at all
three time points. There were 14 male and 9 female
patients with a median age of 59 years (range 41–
78 years). Five patients had stage IIIB and 18 stage IV
(Table 1). After a median follow-up of 10.9 months (95%
CI 9.2–12.7) 12 patients remain alive of whom 9 are
progression-free. Median PFS was 5.9 months (95% CI
5.4–6.4) and median OS 12.4 months (95% CI 10.3–
14.6), which is similar to the total clinical trial patient
population (PFS 4.6 months and OS 12.0 months)
(Table 1).
Anatomical response evaluation
Mean tumour size decreased from 5.6 cm (range 1.9–
14.0 cm) at baseline to 4.8 cm (range 1.6–11.0 cm) at
week 3 and 4.6 cm (range 1.4–10.1 cm) at week 6. The
mean change in size was −13% (range −45 to +5%) and
−19% (range −38 to 0%) respectively. The RECIST
response was unavailable for 2 out of the 23 patients:
one patient discontinued treatment before the week 6
response CT and one patient was not evaluable for
Fig. 2 Box plots showing a tumour blood ﬂow at baseline and 3
and 6 weeks after starting treatment and b percentage tumour
change after 3 and 6 weeks of treatment. Tumour blood ﬂow
decreased signiﬁcantly after 3 and 6 weeks (p<0.001)
2893response because of the development of a large cavity
superimposed with infection. Of the evaluable patients, 6
had PR and 15 SD as their best objective primary tumour
response according to RECIST (Table 1). Nine patients
developed extensive cavitations during treatment. No
tumour cavitation was observed at baseline. According
to the Crabb criteria 11 patients had PR and 10 SD.
Tumour blood ﬂow
There was a wide variation in baseline BF, ranging
from 10.5 to 125.0 ml/100 g/min but mean BF values
did not differ between the two centres. Mean baseline
BF was 39.2±29.9 ml/100 g/min. After starting treat-
ment, BF decreased in all but one patient after 3 weeks
(this patient showed a subsequent decrease in BF at
week 6) and all except one patient after 6 weeks (this
patient had an initial decrease at week 3) compared
with baseline. An example is shown in Fig. 1.T h e
mean perfusion decreased signiﬁcantly to 15.1±
16.5 ml/100 g/min (range 0 to 60.0 ml/100 g/min; p<
0.001) at week 3 with a mean decrease of 60±37%
(range −100 to +7%) and to 9.4±15.4 ml/100 g/min
(range 0 to 66.4 ml/100 g/min; p<0.001) at week 6
with a mean decrease of 72±35% (range −100 to
+18%) compared with baseline (Fig. 2). As a result of
extensive necrosis and/or cavitation of the primary
tumour, BF was not measurable in seven patients at
week 3 and nine patients at week 6, and was recorded
as being zero. Baseline BF was lower in patients who
developed extensive cavitations (31.2±21.0 ml/100 g/
min) compared with those who did not (50.0±35.2 ml/
100 g/min), p=0.012.
Tumour blood ﬂow and anatomical response evaluation
Baseline BF was not signiﬁcantly different in responders
versus non-responders according to both the RECIST
(mean 28.3±12.3 ml/min/100 g versus 34.3±21.3 ml/
100 g/min, p=0.79) and the Crabb methods (mean 27.1±
10.8 ml/100 g/min versus 38.6±24.5 ml/100 g/min, p=
0.38) (Fig. 3).
After 3 weeks of treatment RECIST responders had a
signiﬁcantly lower tumour BF than non-responders (mean
4.2±7.8 ml/100 g/min versus 17.7±13.4 ml/100 g/min, p
=0.03; Fig. 3 a). SD was the best tumour response in the
patient with an increase in tumour BF at week 3. After
6 weeks all RECIST responders had necrosis and/or
extensive cavitation of the primary tumour with a BF
value set to zero. Three additional patients, considered to
be RECIST non-responders, had necrosis and/or tumour
cavitation with no measurable BF. BF in responders was
Fig. 3 Box plots showing
tumour blood ﬂow according to a
RECIST tumour response and b
tumour response according to
Crabb. Responders (unshaded
blocks) had signiﬁcantly lower
blood ﬂow after 3 and 6 weeks of
treatment compared with non-
responders (shaded blocks)
according to both response
methods
2894also signiﬁcantly lower than in non-responders at week 6
(mean 0±0 versus 13.4±16.9 ml/100 g/min, p=0.04;
Fig. 3a). SD was the best tumour response in the patient
with an increase in BF at week 6.
When incorporating the Crabb criteria into the objective
response assessment all but one out of the seven patients
in whom BF was not measurable after 3 weeks and all but
one out of the nine patients in whom the BF was not
measurable at week 6 were considered responders. BF
after 3 and 6 weeks of treatment were lower in responders
than in non-responders (mean 6.5±9.5 ml/100 g/min
versus 20.8±13.2 ml/100 g/min, p=0.01 and mean 3.2±
5.9 ml/100 g/min versus 17.3±19.8 ml/100 g/min, p=0.01
respectively; Fig. 3b). Again, SD was the best tumour
response in the two patients with an increase in tumour BF
at weeks 3 and 6.
Regarding the percentage change in BF, RECIST
responders demonstrated a signiﬁcantly larger decrease
in BF after 3 weeks (mean −85±30% versus −49±34%,
p=0.03) and 6 weeks of treatment (mean −100±0%
versus −60±36%, p=0.004) (Fig. 4a). This was similarly
seen in Crabb responders versus non-responders at weeks
3( −80±30% versus −40±32%, p=0.01) and 6 (−88±22%
versus −51±38 %, p=0.01; Fig. 4b).
Tumour blood ﬂow and progression-free/overall survival
There was no association between pre-treatment abso-
lute BF values relative to the median and PFS. Patients
with a decrease larger than the median decrease of 91%
at week 6 showed a trend towards a longer PFS than
those with a smaller decrease (7.1 months [95% CI 5.1–
9.0] versus 5.7 [95% CI 0–14.2], p=0.06; Fig. 5). This
was not apparent at week 3. Neither absolute change
nor change in BF relative to the median was associated
with OS.
Discussion
This is, to our knowledge, the ﬁrst study to assess
tumour perfusion measured by DCE-CT in patients
with NSCLC receiving anti-angiogenic and anti-EGFR
therapy. We found serial DCE-CTs to be feasible, well
tolerated and easily integrated into the routine clinical
practice with perfusion measurements possible in most
patients. Tumour cavitation, beam-hardening artefacts
and small tumour size were the main reasons why
perfusion could not be reliably measured. The last two Fig. 4 Bar chart showing percentage change in tumour blood ﬂow
according to a RECIST tumour response and b tumour response
according to Crabb. Responders (unshaded blocks)h a da
signiﬁcantly larger decrease in blood ﬂow after 3 and 6 weeks of
treatment compared with non-responders (shaded blocks) according
to both response methods
Fig. 5 Kaplan–Meier curve of progression-free survival (PFS).
Patients with a decrease in tumour blood ﬂow larger than the
median decrease at week 6 (solid line) tended to have a longer
PFS versus patients with a change in blood ﬂow smaller than the
median decrease at week 6 (dashed line)( p=0.06)
2895of these factors are known to prohibit perfusion
measurements [27, 28].
Tumour cavitation frequently occurs in patients receiv-
ing angiogenesis inhibitors [20]. We found that baseline
tumour BF was lower in patients who developed extensive
cavitations compared with those who did not. In some
cases cavitations posed a challenge for BF measurements.
On the one hand, when the cavitation was limited, BF in
the remaining tumour volume could be quantiﬁed. How-
ever, perfusion is not distributed homogeneously through-
out tumours [27, 29]. Measuring average BF in the
remaining peripheral tumour volume may overestimate
BF and thus, in part, explain the wide variation in BF
seen. On the other hand, in some patients cavitation was
so extensive that insufﬁcient tumour tissue remained to
enable a reliable measurement of BF and this was
recorded as zero. Although, we assigned a value of zero
in these patients it is clear that BF was not truly absent,
but simply not measurable by DCE-CT.
Although the sample size is small and there was a wide
variation in absolute BF levels, tumour BF decreased in
all but one patient after 3 and 6 weeks of treatment with
sorafenib and erlotinib. Additionally, the mean BF of the
whole group decreased signiﬁcantly following 3 and
6 weeks of treatment. This may reﬂect the proposed anti-
angiogenic mechanism of action of sorafenib. Bevacizu-
mab, a monoclonal antibody angiogenesis inhibitor, has
similarly been shown to reduce tumour perfusion in
colorectal cancer [7, 10, 30]. For NSCLC, a reduction in
tumour blood volume is reported after administration of
combretastatin, a vascular disrupting agent, in patients
who had an increase in tumour permeability following
radiotherapy and after treatment with N-nitro-L-arginine, a
nitric oxide synthesis (NOS) inhibitor [29, 31].
On the other hand, other studies have also shown
changes in tumour vascular parameters in patients with
NSCLC receiving “non-vascular targeting” therapies.
Kiessling et al. describe a reduction in tumour perfusion
in a patient after two cycles of chemotherapy [27]. Wang
et al. found a signiﬁcant decrease in blood ﬂow and
volume in patients responding to (chemo)radiotherapy
[32]. The decrease in tumour BF in our study may thus
reﬂect a general therapy effect.
Currently standard response assessment by RECIST is
based on anatomical measurements with response deﬁned
as a decrease in tumour size greater than 30%. However,
anatomical changes lag behind functional changes and
responses based on anatomical assessments may become
apparent after prolonged treatment duration. We demon-
strated a signiﬁcant difference in tumour perfusion in
objective (anatomical) responders compared with non-
responders after only 3 weeks of treatment, with respond-
ers having lower BF levels than non-responders. This is
partly explained by the development of extensive cavita-
tions in responders as discussed above. More importantly,
however, a larger decline in BF after 6 weeks of treatment
was associated with a trend towards a longer PFS. To our
knowledge, only one other study has investigated the
correlation between the anti-vascular effect of treatment
and outcome in NSCLC. Although there were no
signiﬁcant changes in the whole group, responders to
(chemo)radiotherapy had a signiﬁcant decrease in tumour
blood ﬂow and volume, and patients with a decrease in
permeability–surface area product had a longer PFS and
OS [32].
Despite the encouraging results of our study, a number
of unresolved issues remain regarding DCE-CT. The
optimal timing of response assessment of anti-angiogenic
therapy is unknown. Jain’s concept of a transient normal-
isation of tumour vasculature and improved tumour BF
with anti-angiogenic treatment, followed by vascular
pruning and a reduction in tumour blood ﬂow, is estimated
to occur within the ﬁrst week of anti-angiogenic therapy
[7, 33, 34]. We performed our ﬁrst follow-up DCE-CT
after 3 weeks of treatment and therefore most likely
beyond this normalisation period. Another question con-
cerns the reproducibility of whole tumour perfusion
measurements [11]. We plan to determine the reproduci-
bility of our perfusion measurements in a follow-up study.
Additionally, the magnitude of change in tumour perfu-
sion which is clinically relevant and the optimal temporal
resolution of DCE-CT for the calculation of tumour
vascular parameters remain unknown. In stroke and
colorectal patients acquisition intervals of more than 1 s
and more than 3 s, respectively, inﬂuence perfusion
measurements [35–37]. We used a temporal resolution of
4 s because a higher temporal resolution would not have
permitted whole tumour measurements.
Limitations of DCE-CT are the current lack of stand-
ardised protocols [38], the requirement of breath holding
during image acquisition to prevent motion artefact and
beam-hardening artefacts of tumours located close to large
central blood vessels giving potentially false positive
results. However, compared with other imaging techni-
ques used to assess tumour perfusion, DCE-CT is cheap,
simple, widely available, has high spatial resolution and
can be integrated into existing CT protocols.
In conclusion, serial DCE-CTs appear to be feasible in
patientswithNSCLC.Usingthistechniquewedemonstrated
ad e c r e a s ei nt u m o u rb l o o dﬂow following sorafenib and
erlotinib therapy. Moreover, early changes in blood ﬂow
were predictive of objective response and tended to indicate
a longer progression-free survival. Further studies are
needed but our data suggest that tumour perfusion may be
valuable in the early response monitoring of anti-angiogenic
agents, with larger reductions reﬂecting greater treatment
efﬁcacy. Early response methods will enable earlier dis-
continuation of ineffective treatment, thereby limiting
unnecessary side effects and enabling earlier switching to
other, potentially effective, therapy.
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